Chronic Insomnia Market Forecast 2034: Emerging Sleep Therapies and Rising Disease Burden to Drive Significant Market Growth, Says DelveInsight

The Chronic Insomnia market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Chronic Insomnia pipeline products will significantly revolutionize the Chronic Insomnia market dynamics.

DelveInsight's "Chronic Insomnia Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Chronic Insomnia, historical and forecasted epidemiology as well as the Chronic Insomnia market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Chronic Insomnia market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Chronic Insomnia Market Forecast - https://www.delveinsight.com/sample-request/chronic-insomnia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Some of the key facts of the Chronic Insomnia Market Report:
• The Chronic Insomnia market size was valued approximately USD 333 million in 2021 and is anticipated to grow with a significant CAGR during the study period (2020-2034).
• In April 2026, Nexalin Technology, Inc. (Nasdaq: NXL), a pioneer in non-invasive Deep Intracranial Frequency Stimulation (DIFSTM), has announced the online publication of a peer-reviewed study in Psychotherapy and Psychosomatics. The study highlights notable clinical improvements and observable modulation of brain networks in patients with chronic insomnia who were treated using the company's high-power stimulation protocol at 15 mA and 77.5 Hz.
• A recent survey by the American Academy of Sleep Medicine indicates that 12% of Americans have been diagnosed with chronic insomnia.
• The International Classification of Sleep Disorders, 3rd edition (ICSD-3) reports that approximately 14% of the adult population in Spain suffers from chronic insomnia disorder.
• According to secondary research, insomnia is more common among middle-aged and older adults, women, and those with underlying medical or psychiatric conditions.
• Key Chronic Insomnia Companies: IDORSIA, EISAI, Janssen Research & Development, Takeda, and others
• Key Chronic Insomnia Therapies: QUVIVIQ (daridorexant), DAYVIGO (lemborexant), Seltorexant, Ramelteon and zolpidem, and others
• The Chronic Insomnia epidemiology based on gender analyzed that Chronic Insomnia is more prominent in females in comparison to males
• The Chronic Insomnia market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Chronic Insomnia pipeline products will significantly revolutionize the Chronic Insomnia market dynamics.

Chronic Insomnia Overview
Chronic insomnia is a long-term sleep disorder characterized by difficulty falling asleep, staying asleep, or waking up too early, occurring at least three times a week for three months or more. It leads to daytime fatigue, impaired concentration, mood disturbances, and reduced quality of life. Causes can include stress, medical conditions, medications, or poor sleep habits.

Get a Free sample for the Chronic Insomnia Market Report:
https://www.delveinsight.com/report-store/chronic-insomnia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Chronic Insomnia Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Chronic Insomnia Epidemiology Segmentation:
The Chronic Insomnia market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:
• Total Prevalence of Chronic Insomnia
• Prevalent Cases of Chronic Insomnia by severity
• Gender-specific Prevalence of Chronic Insomnia
• Diagnosed Cases of Episodic and Chronic Chronic Insomnia

Download the report to understand which factors are driving Chronic Insomnia epidemiology trends @ Chronic Insomnia Epidemiology Forecast
https://www.delveinsight.com/sample-request/chronic-insomnia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Chronic Insomnia Drugs Uptake and Pipeline Development Activities
QUVIVIQ (daridorexant) - IDORSIA
QUVIVIQ is an oral dual orexin receptor antagonist (DORA) designed to treat insomnia in adults by inhibiting orexin neuropeptides that promote wakefulness. Unlike traditional sedatives, the therapy works by reducing excessive wake signals in the brain, thereby supporting healthier sleep initiation and maintenance. The medication is administered once nightly, approximately 30 minutes before bedtime, ensuring at least seven hours remain before waking. In January 2022, the US FDA approved QUVIVIQ 25 mg and 50 mg doses for adults experiencing difficulties with sleep onset and/or sleep maintenance.

DAYVIGO (lemborexant) - EISAI
DAYVIGO (lemborexant), developed by Eisai, is a small-molecule orexin receptor antagonist targeting OX1R and OX2R receptors. By blocking orexin A and orexin B signaling pathways, the drug helps decrease wakefulness and improve sleep quality in patients with insomnia. The therapy received US FDA approval in December 2019 for the treatment of insomnia. Subsequently, in January 2020, Eisai obtained manufacturing and marketing approval for DAYVIGO in Japan, further strengthening its global presence in the insomnia treatment landscape.

Chronic Insomnia Therapies and Key Companies
• QUVIVIQ (daridorexant): IDORSIA
• DAYVIGO (lemborexant): EISAI
• Seltorexant: Janssen Research & Development
• Ramelteon and zolpidem: Takeda

Discover more about therapies set to grab major Chronic Insomnia market share @ Chronic Insomnia Treatment Market
https://www.delveinsight.com/sample-request/chronic-insomnia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Chronic Insomnia Market Drivers
• Increasing Prevalence
• Personalization of therapies

Chronic Insomnia Market Barriers
• Issues with diagnosis and poor knowledge
• Use of off-label drugs
• High economic burden

Scope of the Chronic Insomnia Market Report
• Study Period: 2020-2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Chronic Insomnia Companies: IDORSIA, EISAI, Janssen Research & Development, Takeda, and others
• Key Chronic Insomnia Therapies: QUVIVIQ (daridorexant), DAYVIGO (lemborexant). Seltorexant, Ramelteon and zolpidem, and others
• Chronic Insomnia Therapeutic Assessment: Chronic Insomnia current marketed and Chronic Insomnia emerging therapies
• Chronic Insomnia Market Dynamics: Chronic Insomnia market drivers and Chronic Insomnia market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Chronic Insomnia Unmet Needs, KOL's views, Analyst's views, Chronic Insomnia Market Access and Reimbursement

Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679
https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

This release was published on openPR.